118 related articles for article (PubMed ID: 9395171)
1. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
2. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
[TBL] [Abstract][Full Text] [Related]
4. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
[TBL] [Abstract][Full Text] [Related]
5. The novel late Na
Rajamani S; Liu G; El-Bizri N; Guo D; Li C; Chen XL; Kahlig KM; Mollova N; Elzein E; Zablocki J; Belardinelli L
Br J Pharmacol; 2016 Nov; 173(21):3088-3098. PubMed ID: 27449698
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
Circulation; 2024 Jun; ():. PubMed ID: 38939955
[TBL] [Abstract][Full Text] [Related]
7. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7).
Tsuboi M; Antzelevitch C
Heart Rhythm; 2006 Mar; 3(3):328-35. PubMed ID: 16500306
[TBL] [Abstract][Full Text] [Related]
8. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
Mazzanti A; Maragna R; Faragli A; Monteforte N; Bloise R; Memmi M; Novelli V; Baiardi P; Bagnardi V; Etheridge SP; Napolitano C; Priori SG
J Am Coll Cardiol; 2016 Mar; 67(9):1053-1058. PubMed ID: 26940925
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.
Nasilli G; Yiangou L; Palandri C; Cerbai E; Davis RP; Verkerk AO; Casini S; Remme CA
Europace; 2023 Jun; 25(6):. PubMed ID: 37369559
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
[TBL] [Abstract][Full Text] [Related]
11. Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study.
Miller JA; Moise N; Weinberg SH
Am J Physiol Heart Circ Physiol; 2023 Feb; 324(2):H179-H197. PubMed ID: 36487185
[TBL] [Abstract][Full Text] [Related]
12. The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review.
Gelman I; Sharma N; Mckeeman O; Lee P; Campagna N; Tomei N; Baranchuk A; Zhang S; El-Diasty M
Biomed Pharmacother; 2024 May; 174():116513. PubMed ID: 38565056
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation.
Zhang J; Luo D; Li F; Li Z; Gao X; Qiao J; Wu L; Li M
Oxid Med Cell Longev; 2021; 2021():3520034. PubMed ID: 34659631
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying age-associated manifestation of cardiac sodium channel gain-of-function.
Nowak MB; Poelzing S; Weinberg SH
J Mol Cell Cardiol; 2021 Apr; 153():60-71. PubMed ID: 33373643
[TBL] [Abstract][Full Text] [Related]
15. Indications for mexiletine in the new ESC guidelines and beyond.
Vamos M; Zsigmond EJ; Hohnloser SH
Expert Opin Pharmacother; 2023; 24(12):1403-1407. PubMed ID: 37306465
[TBL] [Abstract][Full Text] [Related]
16. Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Johannesen L; Vicente J; Mason JW; Erato C; Sanabria C; Waite-Labott K; Hong M; Lin J; Guo P; Mutlib A; Wang J; Crumb WJ; Blinova K; Chan D; Stohlman J; Florian J; Ugander M; Stockbridge N; Strauss DG
Clin Pharmacol Ther; 2016 Feb; 99(2):214-23. PubMed ID: 26259627
[TBL] [Abstract][Full Text] [Related]
17. The congenital long QT syndrome Type 3: An update.
Pérez-Riera AR; Barbosa-Barros R; Daminello Raimundo R; da Costa de Rezende Barbosa MP; Esposito Sorpreso IC; de Abreu LC
Indian Pacing Electrophysiol J; 2018; 18(1):25-35. PubMed ID: 29101013
[TBL] [Abstract][Full Text] [Related]
18. Role of late sodium channel current block in the management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
[TBL] [Abstract][Full Text] [Related]
19. Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality.
Olleik F; Kamareddine MH; Spears J; Tse G; Liu T; Yan GX
Pacing Clin Electrophysiol; 2023 Nov; 46(11):1348-1356. PubMed ID: 37846818
[TBL] [Abstract][Full Text] [Related]
20. Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.
Sabir IN; Li LM; Jones VJ; Goddard CA; Grace AA; Huang CL
Pflugers Arch; 2008 Jan; 455(4):637-51. PubMed ID: 17805561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
